United Biotech, a fast growing Indian pharmaceutical company, is diversifying into the oncology segment starting with the launch of its new oncology division at an initial cost of Rs 15 crore.
The company has put up a state of the art facility at Baddi, Himachal Pradesh with dedicated facility specifically meant for oncology. This new division has tied up with Blausiegel, a Brazilian company, for its entire range of biotechnology products used specifically for the treatment of cancer while discussions are underway with four global pharma companies for strategic tie ups for this oncology division.
By the launch of this division the company aims to manufacture and market molecules that are currently being exclusively marketed by multinationals and are priced almost 10 times higher than the pricing United Biotech will offer for the same products.
"United Biotech will meet challenges of tomorrow through differentiation from competing products and generics in the oncology therapeutic segment. To funnel our short term growth plan in the oncology segment we aim to tap the global oncology generics business opportunity worth US$ 14-15 billion dollars in the next 5 years while our long term growth plan in the oncology segment will come through new drug delivery systems (NDDS) being developed by our in-house scientists and supplementing its strength through alliances. United Biotech will follow multi-pronged strategies for its continuous growth across all therapeutic segments that it is currently in operation", said R K Dewan, vice president marketing, United Biotech.
In addition to Indian health care reforms designed to reduce costs, there is an escalation of competition among both domestic and foreign pharmaceutical companies. We are determined to improve our business performance by introducing new products, expanding our product range while increasing market shares of our existing products. We have introduced a range of policies designed to strengthen our marketing capabilities, our quality assurance and our R&D, while also enhancing our cost-competitiveness, management capabilities and human resources," Dewan added.
United Biotech was established in 1997 with an aim to bring in new products and new technologies to the Indian Healthcare Industry. It has a new state of art WHO-cGMP compliant and UKMHRA approvable plant at Baddi, Himachal Pradesh and is looking forward to expand further 5 new divisions. It currently has technical and marketing collaborations with a number of research based multinational companies from Europe and South America. Its proprietary manufacturing processes, in-house R&D scientists and technologists are developing NDDS. Product control procedures are carried out according to international WHO-GMP, GAMP, GLP and GCP standards.